AMOYTOP(SH:688278)2021-10-27 16:00Financial Performance - The company's revenue for Q3 2021 reached ¥340,550,329.12, representing a year-over-year increase of 69.46%[4] - Net profit attributable to shareholders for Q3 2021 was ¥55,583,634.62, an increase of 87.46% compared to the same period last year[4] - The net profit excluding non-recurring gains and losses for Q3 2021 was ¥67,382,545.10, reflecting a significant increase of 121.59% year-over-year[4] - Total revenue for the first three quarters of 2021 reached ¥809,788,878.19, a significant increase of 44.4% compared to ¥560,521,811.85 in the same period of 2020[19] - The net profit for the current period is 127,688,290.01 RMB, representing an increase of 67.5% compared to 76,262,628.71 RMB in the previous period[20] - The total profit for the current period is 164,938,702.91 RMB, up from 89,561,251.71 RMB, indicating an increase of 84.3%[20] - Operating profit has risen to 191,556,085.91 RMB, compared to 103,989,914.26 RMB, reflecting a growth of 84.0%[20] Assets and Liabilities - The total assets at the end of the reporting period amounted to ¥1,346,988,287.75, a 12.93% increase from the end of the previous year[5] - The company's total assets as of Q3 2021 amounted to ¥1,346,988,287.75, compared to ¥1,192,733,961.09 in Q3 2020, representing an increase of 12.9%[18] - The total liabilities for Q3 2021 were ¥239,240,546.69, up from ¥192,334,510.04 in Q3 2020, indicating a rise of 24.4%[17] - The total liabilities amounted to $192.33 million, an increase from $204.72 million in the previous period[28] - Total equity attributable to shareholders reached ¥1,000,399,451.05, indicating a stable financial position[30] Cash Flow - The cash flow from operating activities for the year-to-date period was ¥174,952,932.27, reflecting a year-over-year increase of 191.72%[5] - Cash flow from operating activities generated a net amount of 174,952,932.27 RMB, significantly higher than 59,972,038.67 RMB from the previous period, marking an increase of 191.5%[24] - Cash inflow from investment activities totaled 684,118,316.80 RMB, compared to 603,543,041.26 RMB, showing an increase of 13.4%[24] - The total cash and cash equivalents at the end of the period amounted to $310.42 million, up from $287.62 million previously[25] Shareholder Information - Total number of common shareholders at the end of the reporting period is 7,371, with the top ten shareholders holding a combined 85.85% of shares[10] - Yang Ying, the largest shareholder, holds 138,077,266 shares, representing 33.94% of total shares[10] - The second largest shareholder, Tonghua Dongbao Pharmaceutical Co., Ltd., holds 114,185,114 shares, accounting for 28.07%[10] - The company has no pledged, marked, or frozen shares among the top ten shareholders[10] Research and Development - Research and development expenses totaled ¥38,873,996.54, accounting for 11.42% of revenue, a decrease of 7.36 percentage points compared to the previous year[5] - Research and development expenses increased to ¥56,853,312.07 in 2021 from ¥44,868,117.76 in 2020, marking a growth of 26.7%[19] Donations and Social Responsibility - The company completed cash donations of 5.25 million RMB for the "China Chronic Hepatitis B Clinical Cure (Everest) Project" during the reporting period[13] - The company has donated a total of 250,000 doses of Peginterferon during the project period, fulfilling its donation obligations[13] - The company plans to donate a total of 20 million RMB to the "China Reducing Hepatitis B Patients' Liver Cancer Incidence Research (Oasis) Project" over six years, with 650,000 RMB donated as of September 30, 2021[13] - The company has completed the donation of 116,300 doses of Peginterferon under the Beijing Red Heart Communication Public Welfare Foundation agreement[13] Financial Adjustments and Standards - The company adopted new leasing standards effective January 1, 2021, impacting financial statement adjustments[30] - The company has not reported any audit opinions applicable for the financial statements as of September 30, 2021[14]